e-drug
[Top] [All Lists]

[e-drug] Independent Drug and Healthcare Newsletter for April 2018

E-DRUG: Independent Drug and Healthcare Newsletter for April 2018
------------------------------------------------------------------------------------

Independent Drug & Healthcare Newsletter from the non-profit journal  Prescrire 
International

Newsletter, April 2018
> View the contents
http://english.prescrire.org/en/SummaryDetail.aspx?Issueid=192

If your friends or colleagues would be interested, forward this email and 
invite them to sign up for the free Newsletter.
http://english.prescrire.org/en/83/552/0/0/About.aspx

Like what you see?
Subscribe to Prescrire International
http://english.prescrire.org/en/83/178/0/0/About.aspx

In Prescrire's Spotlight this month
--------------------------------------------------------------------------------
FEATURED REVIEW  Treating intermittent claudication: first encourage patients 
to follow a walking exercise programme
Some patients with lower limb peripheral artery disease experience pain while 
walking, due to a reduced ability to increase arterial circulation. What is the 
harm-benefit balance of treatments aimed at improving their walking capacity?
> Read more
http://english.prescrire.org/en/81/168/55000/0/NewsDetails.aspx

--------------------------------------------------------------------------------
FREE DOWNLOAD  In the April issue of Prescrire International: Towards better 
patient care - drugs to avoid in 2018
Prescrire's annual review of drugs to avoid covers all the drugs examined by 
Prescrire between 2010 and 2017 that are authorised in the European Union or in 
France. We identified 90 drugs that are more harmful than beneficial in all the 
indications for which they have been authorised.
> Read more
http://english.prescrire.org/en/81/168/54999/0/NewsDetails.aspx

--------------------------------------------------------------------------------
Hepatitis C: sofosbuvir + velpatasvir (Epclusa°) represents an advance for some 
patients
The combination sofosbuvir + velpatasvir (Epclusa°) offers a therapeutic 
advance in the treatment of hepatitis C, especially in patients infected by a 
genotype 2 virus. But the uncertainty surrounding its adverse effects is 
unacceptable.
> Read more
http://english.prescrire.org/en/81/168/55001/0/NewsDetails.aspx

--------------------------------------------------------------------------------
New drugs and indications in 2017: numerous innovations offering no progress
Marketing authorisations often granted too hastily: patients are exposed to 
medicines with uncertain harm-benefit balances.
> Read more
http://english.prescrire.org/en/81/168/55002/0/NewsDetails.aspx

--------------------------------------------------------------------------------
Prescrire's ratings of new products and indications over the past 10 years
Each spring, Prescrire International publishes a recap of the drugs reviewed in 
our French edition during the previous year. It includes a table summing up the 
ratings Prescrire's editors gave to the new drugs and indications reviewed 
during each of the past ten years.
> Read more
http://english.prescrire.org/en/81/168/55003/0/NewsDetails.aspx

Share this with a friend or colleague: Forward this email

Get this from a friend? Sign up here
http://english.prescrire.org/en/83/552/0/0/About.aspx

Prescrire International <international@prescrire.org>

<Prev in Thread] Current Thread [Next in Thread>
  • [e-drug] Independent Drug and Healthcare Newsletter for April 2018, Prescrire International <=